STELARA® is a subcutaneously administered biologic approved by the US Food and Drug Administration in September 2009 for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. This Clinical Brief summarizes the 2 phase 3 multicenter, randomized, double-blind, placebo-controlled trials that demonstrated the efficacy and safety of STELARA®.
More like this
- Unmet Needs in the Management of Plaque Psoriasis
- Considerations for the Clinical Assessment of the Patient With Plaque Psoriasis
- Treating Psoriasis as a T-Cell Mediated Disease
- Managed Care Best Practices In the Treatment and Management of Psoriasis
- Review of the Clinical Information for SIMPONI™ (golimumab) In Rheumatoid Arthritis
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweißen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.